Clonidine Patch for Tourette Syndrome With Attention-Deficit/Hyperactivity Disorder
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective To explore the efficacy and safety of clonidine adhesive patch in Tourette syndrome (TS) patients with comorbid attentiondeficit/hyperactivity disorder (ADHD).Methods This study was conducted on a sample of children and adolescents with TS who had comorbid ADHD between May 2012 and March 2015. The patients were diagnosed according to Diagnostic and Statistical Manual of Mental Disorders Fourth Edition, and were randomly assigned to four different dose groups: 1.0 mg/week, 1.5 mg/week, 2.0 mg/week and placebo group, and the symptom was evaluated by Swanson, Nolan, and Pelham Rating Scale, Version IV (SNAP-IV) and Yale Global Tic Severity Scale scales every 2 weeks. The primary outcome was tic disorders (TD) effective rate at week 8.Results One hundred and twenty-seven TS patients with comorbid ADHD in 2.0 mg/week (n=35), 1.5 mg/week (n=27), 1.0 mg/week (n=36) and placebo groups (n=29) were included in this subgroup analysis. The TD effective rate of the 2.0 mg, 1.5 mg, and 1.0 mg groups at week 8 were significantly better than that in placebo group (85.7%, 81.5%, and 86.1% vs. 20.7%, all p<0.0001). All groups demonstrated significant improvements in SNAP-IV total scale scores compared to baseline (p=0.0004), with treatment groups showing only a trend for better performance compared to placebo group at week 8, without statistical differences (22.1±15.41, 21.3±11.96, and 21.2±12.48 vs. 26.0±13.37, p=0.3385). A total of 9 adverse reactions occurred, all recovered spontaneously without additional medication.Conclusion Clonidine adhesive patch could safely and effectively reduce the tic symptoms of TS patients with comorbid ADHD, and might be potentially helpful in the ADHD symptoms control.
Abstract
Objective To explore the efficacy and safety of clonidine adhesive patch in Tourette syndrome (TS) patients with comorbid attentiondeficit/hyperactivity disorder (ADHD).Methods This study was conducted on a sample of children and adolescents with TS who had comorbid ADHD between May 2012 and March 2015. The patients were diagnosed according to Diagnostic and Statistical Manual of Mental Disorders Fourth Edition, and were randomly assigned to four different dose groups: 1.0 mg/week, 1.5 mg/week, 2.0 mg/week and placebo group, and the symptom was evaluated by Swanson, Nolan, and Pelham Rating Scale, Version IV (SNAP-IV) and Yale Global Tic Severity Scale scales every 2 weeks. The primary outcome was tic disorders (TD) effective rate at week 8.Results One hundred and twenty-seven TS patients with comorbid ADHD in 2.0 mg/week (n=35), 1.5 mg/week (n=27), 1.0 mg/week (n=36) and placebo groups (n=29) were included in this subgroup analysis. The TD effective rate of the 2.0 mg, 1.5 mg, and 1.0 mg groups at week 8 were significantly better than that in placebo group (85.7%, 81.5%, and 86.1% vs. 20.7%, all p<0.0001). All groups demonstrated significant improvements in SNAP-IV total scale scores compared to baseline (p=0.0004), with treatment groups showing only a trend for better performance compared to placebo group at week 8, without statistical differences (22.1±15.41, 21.3±11.96, and 21.2±12.48 vs. 26.0±13.37, p=0.3385). A total of 9 adverse reactions occurred, all recovered spontaneously without additional medication.Conclusion Clonidine adhesive patch could safely and effectively reduce the tic symptoms of TS patients with comorbid ADHD, and might be potentially helpful in the ADHD symptoms control.
참고문헌 (30)
- Efron D, "Tics and Tourette syndrome", J Paediatr Child Health, 54, pp.1148~1153 (2018)
- Singer HS, "Tics and Tourette syndrome", Continuum(Minneap Minn), 25, pp.936~958 (2019)
- Nilles C, "Tourette syndrome and other tic disorders of childhood", Handb Clin Neurol, 196, pp.457~474 (2023)
- El Malhany N, "Tourette syndrome and comorbid ADHD : causes and consequences", Eur J Pediatr, 174, pp.279~288 (2015)
- Sharma SR, "Autism spectrum disorder : classifica tion, diagnosis and therapy", Pharmacol Ther, 190, pp.91~104 (2018)
- Ueda K, "A comprehensive review of tic disorders in children", J Clin Med, 10, pp.2479~ (2021)
- Pringsheim T, "Practice guideline recommendations summary : treat ment of tics in people with Tourette syndrome and chronic tic disor ders", Neurology, 92, pp.896~906 (2019)
- Roessner V, "Eu ropean clinical guidelines for Tourette syndrome and other tic disor ders-version 2. 0. Part III : pharmacological treatment", Eur Child Adolesc Psychiatry, 31, pp.425~441 (2022)
- Golmirzaei J, "Psychopharmacology of attention-deficit hyperactivity dis order : effects and side effects", Curr Pharm Des, 22, pp.590~594 (2016)
- Osland ST, "Pharmacological treatment for attention deficit hyperactivity disorder(ADHD)in children with co morbid tic disorders", Cochrane Database Syst Rev, 6, pp.CD007990~ (2018)
- Joo SW, "Treatment of children and adolescents with atten tion deficit hyperactivity disorder and", or Tourette’s disorder with cloni dine extended release, 2018, pp.15, 90~93
- Zeng KD, "Efficacy of clonidine in the treatment of children with tic disorder co-morbid with attention deficit hyperactivity disorder", Eur Rev Med Pharmacol Sci, 27, pp.4232~4238 (2023)
- Yang C, "Effectiveness and safety of a clonidine adhesive patch for children with tic disorders : study in a real world practice", Front Neurol, 11, pp.361~ (2020)
- Ke Z, "Efficacy and safety of clonidine adhesive patch in the treatment of childhood tic disorders : a systematic review and meta-analysis", Chinese J Evid Based Pediatr, 11, pp.426~430 (2016)
- Wang S, "Clonidine adhesive patch for the treatment of tic disorders : a systematic review and meta-analy sis", Eur J Paediatr Neurol, 21, pp.614~620 (2017)
- Müller-Vahl KR, "European clinical guidelines for Tourette syndrome and other tic disorders : summary statement", Eur Child Adolesc Psychi atry, 31, pp.377~382 (2022)
- Mechler K, "Evidence-based pharmacological treatment options for ADHD in children and adoles cents", Pharmacol Ther, 230, pp.107940~ (2022)
- Tourette’s Syndrome Study Group, "Treatment of ADHD in children with tics : a randomized controlled trial", Neurology, 58, pp.527~536 (2002)
- Willcutt EG, "Validity of DSM-IV attention deficit", hyperactivity disor der symptom dimensions and subtypes, 2012, pp.121, 991~1010
- Zhou JB, "Reliability and validity of the Chinese ver sion of Swanson, Nolan, and Pelham version IV rating scale-parent form for attention-deficit", hyperactivity disorder, 2013, pp.27, 424~428
- Zhong Y, "Yale global tic severity scale for children with tic disorders : a report on its preliminary application", Sichuan Med J, 21, pp.110~111 (2000)
- Groth C, "Course of Tourette syndrome and comorbidities in a large prospective clinical study", J Am Acad Child Adolesc Psychiatry, 56, pp.304~312 (2017)
- Hirschtritt ME, "Lifetime prevalence, age of risk, and genetic relationships of comor bid psychiatric disorders in Tourette syndrome", JAMA Psychiatry, 72, pp.325~333 (2015)
- Young S, "Females with ADHD : an expert consensus statement taking a lifespan approach providing guidance for the identification and treat ment of attention-deficit", hyperactivity disorder in girls and women, 2020, pp.20, 404~
- Hinshaw SP, "Attention deficit hyperactivity disorder(ADHD) : contro versy, developmental mechanisms, and multiple levels of analysis", Annu Rev Clin Psychol, 14, pp.291~316 (2018)
- Pringsheim T, "Canadian guidelines for the evidence-based treatment of tic dis orders : pharmacotherapy", Can J Psychiatry, 57, pp.133~143 (2012)
- Liu ZS, "Current status, diagnosis, and treatment recommendation for tic disorders in China", Front Psychiatry, 11, pp.774~ (2020)
- Weisman H, "Systematic review : pharmacological treatment of tic disorders--efficacy of anti psychotic and alpha-2 adrenergic agonist agents", Neurosci Biobehav Rev, 37, pp.1162~1171 (2013)
- Augustine F, "Merging the pathophysiology and pharmaco therapy of tics", Tremor Other Hyperkinet Mov(N Y), 8, pp.595~ (2019)
- Seideman MF, "A review of the current treatment of To urette syndrome", J Pediatr Pharmacol Ther, 25, pp.401~412 (2020)